Oncology company Lucence is directing attention to research presentations involving its amplification-based next-generation sequencing (NGS) technology at this week’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
In three separate poster presentations, Lucence will share data showing how a total nucleic acid approach combining circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) in one liquid biopsy test could increase actionable molecular information in lung cancer patients, according to the company.
